Medios
Medios AG is a Berlin-based specialty pharmaceutical company that manufactures and distributes patient-individualized medications, operates GMP-certified compounding facilities, and serves specialty pharmacies, clinics, and pharmaceutical manufacturers across Germany and Europe.
- Company typePublic
- Founded2015
- HeadquartersBerlin, Germany
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Medios does
Medios AG is a Berlin-headquartered, Frankfurt-listed specialty pharmaceutical company that manufactures and distributes patient-individualized medicines, with FY2025 revenue exceeding €2.0 billion and operations spanning Germany, the Netherlands, Belgium, and Spain. The company operates two divisions: Specialty Pharma, which combines pharmaceutical wholesale, GMP-certified patient-specific drug compounding, and cold-chain distribution of high-value therapies (primarily oncology, immunology, and biologics) for partner pharmacies, clinics, and pharmaceutical manufacturers; and Advanced Therapies, a strategic initiative focused on biotechnological precision medicine. Revenue is generated principally through transaction-fee wholesale distribution and GMP compounding services, supplemented by a digital service infrastructure that provides workflow and traceability tools to pharmacy and clinic partners.
The business model is B2B enterprise field sales targeting specialty pharmacies, clinics, pharmaceutical manufacturers, and clinical study sponsors under Germany's regulated reimbursement framework. The platform is vertically integrated across procurement, quality assurance, GMP compounding, cold-chain logistics, and digital workflow tools, serving as critical last-mile infrastructure for personalized medicine in Germany. Go-to-market is relationship-driven, with pricing obtained via direct sales engagement rather than published rates, and customer base distributed across many partner pharmacies and institutions.
Medios has executed a deliberate European platform strategy: the June 2024 close of the Ceban Pharmaceuticals B.V. acquisition (€235.3M cash plus 1.7M shares) added compounding operations in the Netherlands, Belgium, and Spain; founder Manfred Schneider sold a 14.9% stake to Luxempart S.A. to support internationalization; and a January 2026 exclusive distribution partnership with Bedrocan extended reach into medical cannabis with stated plans to expand into Austria, Belgium, Italy, and Spain. Defensive actions have accompanied expansion: the Aschaffenburg production site (~10% of German volume, 32 staff) was closed in mid-2026 to consolidate patient-individual manufacturing amid regulatory and pricing pressure, and FY2026 adjusted EBITDA guidance was cut to €88-92M from €94-102M while revenue guidance was raised to €2.10-2.16B, reflecting a margin-protection posture alongside top-line growth.
Medios firmographics
Firmographics- Name
- Medios
- Legal name
- Medios AG
- Website
- https://medios.ag
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Medios AG is a Berlin-based specialty pharmaceutical company that manufactures and distributes patient-individualized medications, operates GMP-certified compounding facilities, and serves specialty pharmacies, clinics, and pharmaceutical manufacturers across Germany and Europe.
- Ownership category
- akta.pro rank
Medios industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Pharmacy & Biologics Distribution (CRAOAHAD)
- akta.pro secondary industries
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where Medios is headquartered
LocationHeadquarters
- HQ city
- Berlin
- HQ country
- Germany
- HQ region
- Europe
Offices5 records
Markets served
Medios business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Pharmaceutical Supply (Specialty Pharma Trading): Wholesale distribution of high-value specialty pharmaceuticals to partner pharmacies and clinics across Germany. This includes procurement, quality assurance, and distribution of specialty drugs for complex diseases.
- Drug Compounding Services: GMP-certified patient-specific compounding and manufacturing services for individualized medications, primarily serving oncology, immunology, and biologic treatment markets.
- Digital Service Infrastructure: Digital service infrastructure for pharmacy and clinic workflows, providing integration and operational support services.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Medios product offering
Product offeringCore offering
Medios AG manufactures and supplies patient-specific medicinal products through pharmaceutical wholesale, GMP-certified drug compounding for individualized therapies, and cold-chain distribution. The company serves specialty pharmacies, clinics, and pharmaceutical manufacturers across Germany and Europe with a focus on oncology, immunology, and biologic treatments. Operating as a vertically integrated specialty pharma platform, Medios combines procurement, quality assurance, GMP-certified manufacturing, and digital traceability to support personalized medicine delivery.
Product overview
Medios AG operates as a vertically integrated specialty pharma platform combining pharmaceutical wholesale, GMP-certified patient-specific drug compounding, and digital distribution services for high-cost therapies. The platform spans two core divisions: Specialty Pharma (drug supply, patient-individual compounding, and distribution for oncology and autoimmune disorders) and Advanced Therapies (biotechnology precision medicine). The company serves manufacturers, specialty pharmacies, clinics, and pharmaceutical companies across Germany and Europe, supporting its partner-first integration model with cold-chain logistics and digital service infrastructure.
Differentiator
Problem solved
Functional benefit
Products and services
- Specialty Pharma Pharmaceutical wholesale, drug procurement, quality assurance, and distribution of high-value specialty medications for specialty pharmacies, clinics, and pharmaceutical companies. Includes cold-chain logistics and patient-individual manufacturing operations.
- Advanced Therapies Cutting-edge biotechnological precision medicine and advanced therapy products representing the company's strategic initiative in biotechnology-based treatments.
- GMP-Certified Compounding Services
Quantifiable outcome
- Record H1 2026 revenue of €1,075 million, up from €991.7 million in H1 2025
- +1 more outcomes
Companies that use Medios
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
Medios technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Medios partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- BedrocancoreExclusive distribution partnership for medicinal cannabis products. Medios appointed as exclusive distribution partner for Bedrocan's products in Germany, with plans to expand to Austria, Belgium, Italy, and Spain. Medios distributes cannabis produced at Bedrocan's EU-GMP certified facility in Denmark, leveraging existing Cannaflos network for seamless transition. Partnership streamlines procurement for German pharmacists who previously navigated fragmented distribution markets.
- Ceban Pharmaceuticals B.V.coreAcquisition of Ceban Pharmaceuticals B.V., a leading Dutch pharmaceutical compounding platform with operations in Belgium and Spain. Deal involved €235.3 million cash component and 1.7 million Medios shares. Part of strategy to build a European Specialty Pharma platform, expected to significantly boost revenue and profitability by 2024 and 2025. Acquisition completed in June 2024.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Medios competitors and assessment
Company assessmentDirect peers
- Aenova Group: Aenova is one of Europe's largest CDMOs offering solid, semi-solid, liquid, sterile, and biological contract manufacturing services from multiple European sites. Comparable to Medios's GMP-certified compounding and manufacturing operations for high-value drugs, though more diversified across dosage forms.
- NextPharma: NextPharma is a European specialty CDMO focused on sterile liquids, semi-solids, and patient-specific manufacturing across multiple European sites. Directly comparable to Medios's GMP-certified patient-specific compounding and sterile manufacturing capabilities for specialty drugs.
- Stada Arzneimittel AG: Stada is a major German specialty pharmaceutical company with operations in generics, specialty pharma, and consumer health, including compounding and distribution. Comparable to Medios as a Germany-based specialty pharma platform with focus on niche/individualized medicines.
- Dermapharm Holding SE: Dermapharm is a German specialty pharmaceutical manufacturer focused on niche/rare disease products and parallel imports. Comparable to Medios's specialty pharma strategy targeting smaller patient populations with high-value therapies, though with more emphasis on dermatology and rare disease.
- Sanacorp eG: Sanacorp is Germany's largest pharmaceutical wholesale cooperative serving pharmacies with a broad portfolio including specialty drugs. Directly comparable to Medios's pharmaceutical wholesale and distribution activities to German pharmacies, though without the compounding specialization.
- PharmaZell (SEQENS): PharmaZell (now part of SEQENS) is a European specialty API and CDMO with focus on niche molecules and complex manufacturing. Comparable to Medios's specialty pharma positioning, particularly in patient-specific and complex therapies, though concentrated on APIs and complex small molecules.
- Hameln Pharma (Piramal Pharma Solutions): Hameln Pharma (now part of Piramal) is a German specialty CDMO specializing in sterile injectables, ampoules, and complex injectable formulations. Directly comparable to Medios's GMP-certified sterile compounding capabilities, particularly for oncology and individualized injectable therapies.
Broad incumbents
- Recipharm AB: Recipharm is a major European CDMO offering a broad range of pharmaceutical contract manufacturing services across multiple dosage forms and technologies. Comparable to Medios's GMP manufacturing footprint, though much larger and broader in scope (lacks the specialty pharmacy distribution angle).
- Alliance Healthcare (Walgreens Boots Alliance): Alliance Healthcare is a major European pharmaceutical wholesaler and distributor serving pharmacies across multiple countries. Comparable to Medios's wholesale distribution business, but at much greater scale and without the GMP compounding vertical.
Regional players
- Polpharma: Polpharma is the largest Polish pharmaceutical manufacturer and a leading Central/Eastern European specialty pharma player. Comparable to Medios's specialty pharma manufacturing and distribution model, though primarily serving Polish and CEE markets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Medios social profiles
Digital presenceMedios financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medios leadership team
Management profileNumber of profiles
Profiles1 record
Medios subsidiaries and ownership
Company hierarchySubsidiaries2 records
Medios funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medios M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medios
What does Medios do?
Medios AG manufactures and supplies patient-specific medicinal products through pharmaceutical wholesale, GMP-certified drug compounding for individualized therapies, and cold-chain distribution. The company serves specialty pharmacies, clinics, and pharmaceutical manufacturers across Germany and Europe with a focus on oncology, immunology, and biologic treatments. Operating as a vertically integrated specialty pharma platform, Medios combines procurement, quality assurance, GMP-certified manufacturing, and digital traceability to support personalized medicine delivery.
Is Medios a public or private company?
Medios is a public company. It is classified as public and is currently operating.
When was Medios founded?
Medios was founded in 2015. It employs 1,001 to 5,000 people.
Where is Medios based?
Medios is headquartered in Berlin, Germany, in the Europe region.
How does Medios make money?
Three revenue lines are on record. Pharmaceutical Supply (Specialty Pharma Trading) is the primary driver. The others are drug Compounding Services and digital Service Infrastructure.
Who are Medios's main competitors?
Direct peers on record are Aenova Group, NextPharma, Stada Arzneimittel AG, Dermapharm Holding SE, Sanacorp eG, PharmaZell (SEQENS) and Hameln Pharma (Piramal Pharma Solutions). Broad incumbents are Recipharm AB and Alliance Healthcare (Walgreens Boots Alliance). Polpharma is listed as a regional player.
Does Medios have an API?
No public API is recorded for Medios.
What industry is Medios in?
Medios's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is CRAOAHAD, Specialty Pharmacy & Biologics Distribution, with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 325412 and its SIC code is 5122.